Alexandria Phan, MD, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs.
Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).